Kezar Life Sciences, Inc. (KZR) 10-Year Financial Performance & Capital Metrics

KZR • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.Show more

Revenue $0 -100.0%
EBITDA -$90M +18.8%
Net Income -$84M +17.8%
EPS (Diluted) -1.15 +17.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -55% -23.5%
ROIC -51.8% -30.7%
Debt/Equity 0.14 +37.1%
Interest Coverage -56.88 +20.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM35.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM-539.39%

ROCE

10Y Avg-41.96%

5Y Avg-39.5%

3Y Avg-43.04%

Latest-55.27%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	7M	0
Revenue Growth %	-	-	-	-	-	-	-	-	-1%
Cost of Goods Sold+	154K	175K	690K	1.3M	1.54M	1.51M	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-154K	-175K	-690K	-1.3M	-1.54M	-1.51M	0	7M	0
Gross Margin %	-	-	-	-	-	-	-	1%	-
Gross Profit Growth %	-	-0.14%	-2.94%	-0.89%	-0.19%	0.02%	1%	-	-1%
Operating Expenses+	8.99M	8.75M	24.73M	36.68M	41.46M	53.15M	71.16M	118.42M	90.61M
OpEx % of Revenue	-	-	-	-	-	-	-	16.92%	-
Selling, General & Admin	1.62M	2.28M	6.59M	8.68M	10.43M	15.72M	20.15M	26.54M	23.39M
SG&A % of Revenue	-	-	-	-	-	-	-	3.79%	-
Research & Development	7.37M	6.47M	18.14M	28M	31.04M	38.94M	51.01M	85.7M	65.74M
R&D % of Revenue	-	-	-	-	-	-	-	12.24%	-
Other Operating Expenses	0	0	0	0	0	-1.51M	0	6.19M	1.47M
Operating Income+	-8.99M	-8.75M	-24.73M	-37.98M	-43.01M	-54.66M	-71.16M	-111.42M	-90.61M
Operating Margin %	-	-	-	-	-	-	-	-15.92%	-
Operating Income Growth %	-	0.03%	-1.83%	-0.54%	-0.13%	-0.27%	-0.3%	-0.57%	0.19%
EBITDA+	-8.84M	-8.57M	-24.04M	-36.68M	-41.46M	-53.15M	-70.14M	-110.36M	-89.56M
EBITDA Margin %	-	-	-	-	-	-	-	-15.77%	-
EBITDA Growth %	-	0.03%	-1.8%	-0.53%	-0.13%	-0.28%	-0.32%	-0.57%	0.19%
D&A (Non-Cash Add-back)	154K	175K	690K	1.3M	1.54M	1.51M	1.02M	1.07M	1.04M
EBIT	-8.99M	-8.52M	-23.17M	-35.72M	-41.8M	-54.47M	-67.05M	-100.32M	-82.14M
Net Interest Income+	0	0	0	2.25M	1.21M	29K	2.92M	9.55M	6.87M
Interest Income	0	232K	1.56M	2.25M	1.21M	188K	4.11M	11.1M	8.46M
Interest Expense	0	0	0	0	0	159K	1.19M	1.55M	1.59M
Other Income/Expense	0	232K	1.56M	2.25M	1.21M	29K	2.92M	9.55M	6.87M
Pretax Income+	-8.99M	-8.52M	-23.17M	-35.72M	-41.8M	-54.63M	-68.24M	-101.87M	-83.74M
Pretax Margin %	-	-	-	-	-	-	-	-14.55%	-
Income Tax+	0	0	0	-635K	-58K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-8.99M	-8.52M	-23.17M	-35.09M	-41.74M	-54.63M	-68.24M	-101.87M	-83.74M
Net Margin %	-	-	-	-	-	-	-	-14.55%	-
Net Income Growth %	-	0.05%	-1.72%	-0.51%	-0.19%	-0.31%	-0.25%	-0.49%	0.18%
Net Income (Continuing)	-8.99M	-8.52M	-23.17M	-35.09M	-41.74M	-54.63M	-68.24M	-101.87M	-83.74M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.69	-0.65	-1.22	-1.65	-0.95	-1.04	-1.01	-1.40	-1.15
EPS Growth %	-	0.06%	-0.88%	-0.35%	0.42%	-0.09%	0.03%	-0.39%	0.18%
EPS (Basic)	-0.69	-0.65	-1.22	-1.65	-0.95	-1.04	-1.01	-1.40	-1.15
Diluted Shares Outstanding	13.02M	13.02M	19.02M	19.08M	44M	52.76M	67.37M	72.55M	72.9M
Basic Shares Outstanding	13.02M	13.02M	19.02M	19.08M	44M	52.76M	67.37M	72.55M	72.9M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.49M	52.33M	109.81M	81.13M	144.81M	211.65M	285.72M	206.95M	137.49M
Cash & Short-Term Investments	9.75M	51.03M	107.43M	78.21M	140.45M	208.35M	276.56M	201.37M	132.25M
Cash Only	9.75M	51.03M	24.18M	14.95M	21.23M	62.88M	40.46M	35.49M	41.75M
Short-Term Investments	0	0	83.25M	63.26M	119.22M	145.47M	236.1M	165.88M	90.5M
Accounts Receivable	0	0	0	642K	766K	0	0	2.29M	424K
Days Sales Outstanding	-	-	-	-	-	-	-	119.46	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	598K	508K	489K	406K	865K	729K	0	251K	351K
Total Non-Current Assets+	937K	1.9M	4.88M	8.38M	7.03M	6.28M	13.85M	14.29M	7.19M
Property, Plant & Equipment	862K	1.54M	4.59M	8.1M	6.75M	6M	13.17M	8.69M	4.78M
Fixed Asset Turnover	-	-	-	-	-	-	-	0.81x	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	13K	13K	0	0	0	0	0	0	0
Other Non-Current Assets	62K	343K	282K	282K	282K	282K	674K	5.59M	2.42M
Total Assets+	11.42M	54.22M	114.68M	89.51M	151.84M	217.93M	299.57M	221.24M	144.68M
Asset Turnover	-	-	-	-	-	-	-	0.03x	-
Asset Growth %	-	3.75%	1.12%	-0.22%	0.7%	0.44%	0.37%	-0.26%	-0.35%
Total Current Liabilities+	651K	1.48M	3.34M	6M	6.44M	8.21M	11M	17.74M	20.33M
Accounts Payable	466K	547K	193K	823K	2.36M	2.03M	2.48M	8.25M	3.65M
Days Payables Outstanding	1.1K	1.14K	102.09	230.9	557.43	490.21	-	-	-
Short-Term Debt	0	0	0	900K	1.04M	0	0	3.01M	5.22M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	51K	515K	2.41M	2.99M	1.69M	1.97M	2.69M	2.77M	5.22M
Current Ratio	16.11x	35.26x	32.91x	13.52x	22.48x	25.77x	25.98x	11.66x	6.76x
Quick Ratio	16.11x	35.26x	32.91x	13.52x	22.48x	25.77x	25.98x	11.66x	6.76x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	28.2M	78.42M	2.55M	5.46M	4.42M	12.85M	18.7M	15.92M	7.44M
Long-Term Debt	0	0	0	0	0	9.62M	9.83M	10.07M	5.11M
Capital Lease Obligations	0	0	0	5.46M	4.42M	3.22M	8.87M	5.85M	2.33M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	28.2M	78.42M	2.55M	0	0	0	0	0	0
Total Liabilities	28.85M	79.91M	5.88M	11.47M	10.86M	21.06M	29.7M	33.66M	27.77M
Total Debt+	0	0	0	6.36M	5.46M	14.04M	21.26M	18.93M	16.18M
Net Debt	-9.75M	-51.03M	-24.18M	-8.59M	-15.76M	-48.84M	-19.19M	-16.56M	-25.57M
Debt / Equity	-	-	-	0.08x	0.04x	0.07x	0.08x	0.10x	0.14x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-343.77x	-60.05x	-71.89x	-56.88x
Total Equity+	-17.43M	-25.69M	108.8M	78.05M	140.98M	196.88M	269.87M	187.57M	116.92M
Equity Growth %	-	-0.47%	5.24%	-0.28%	0.81%	0.4%	0.37%	-0.3%	-0.38%
Book Value per Share	-1.34	-1.97	5.72	4.09	3.20	3.73	4.01	2.59	1.60
Total Shareholders' Equity	-17.43M	-25.69M	108.8M	78.05M	140.98M	196.88M	269.87M	187.57M	116.92M
Common Stock	1K	1K	19K	19K	46K	56K	68K	73K	7K
Retained Earnings	-17.51M	-26.03M	-49.2M	-84.28M	-126.02M	-180.65M	-248.89M	-350.76M	-434.5M
Treasury Stock	-232K	-451K	0	0	0	0	0	0	0
Accumulated OCI	-150K	-111K	-203K	-196K	-137K	-291K	-923K	-130K	-162K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.76M	-8.11M	-20.79M	-29.88M	-36.95M	-42.44M	-58.85M	-81.64M	-74.21M
Operating CF Margin %	-	-	-	-	-	-	-	-11.66%	-
Operating CF Growth %	-	0.17%	-1.56%	-0.44%	-0.24%	-0.15%	-0.39%	-0.39%	0.09%
Net Income	-8.99M	-8.52M	-23.17M	-35.09M	-41.74M	-54.63M	-68.24M	-101.87M	-83.74M
Depreciation & Amortization	154K	175K	690K	1.3M	1.54M	1.51M	1.02M	1.07M	1.04M
Stock-Based Compensation	128K	203K	1.99M	4.01M	4.94M	7.6M	14.01M	18.14M	13.01M
Deferred Taxes	0	0	0	0	0	1.77M	0	0	0
Other Non-Cash Items	979K	472K	-370K	-979K	317K	91K	-1.18M	-3.68M	-3.23M
Working Capital Changes	-1.05M	30K	62K	881K	-2.01M	1.23M	-4.46M	4.71M	-1.3M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	-469K	81K	1.44M	2.21M	313K	1.22M	1.81M	6.35M	-3.15M
Cash from Investing+	-132K	-389K	-83.9M	20.42M	-56.5M	-28.44M	-91.39M	76.05M	80.43M
Capital Expenditures	-132K	-389K	-1.12M	-607K	-194K	-316K	-1.58M	-1.81M	-29K
CapEx % of Revenue	-	-	-	-	-	-	-	0.26%	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	10K	21.03K	-56.3K	-28.13K	-89.81K	5K	0
Cash from Financing+	36K	49.76M	77.91M	272K	99.64M	112.58M	127.86M	638K	103K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	36K	0	0	0	456K	2.08M	1.32M	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.89M	-8.5M	-21.91M	-30.48M	-37.14M	-42.75M	-60.42M	-83.45M	-74.24M
FCF Margin %	-	-	-	-	-	-	-	-11.92%	-
FCF Growth %	-	0.14%	-1.58%	-0.39%	-0.22%	-0.15%	-0.41%	-0.38%	0.11%
FCF per Share	-0.76	-0.65	-1.15	-1.60	-0.84	-0.81	-0.90	-1.15	-1.02
FCF Conversion (FCF/Net Income)	1.09x	0.95x	0.90x	0.85x	0.89x	0.78x	0.86x	0.80x	0.89x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-55.75%	-37.56%	-38.12%	-32.34%	-29.24%	-44.54%	-55%
Return on Invested Capital (ROIC)	-	-	-469.78%	-36.97%	-33.14%	-30%	-26.77%	-39.63%	-51.8%
Gross Margin	-	-	-	-	-	-	-	100%	-
Net Margin	-	-	-	-	-	-	-	-1455.29%	-
Debt / Equity	-	-	-	0.08x	0.04x	0.07x	0.08x	0.10x	0.14x
Interest Coverage	-	-	-	-	-	-343.77x	-60.05x	-71.89x	-56.88x
FCF Conversion	1.09x	0.95x	0.90x	0.85x	0.89x	0.78x	0.86x	0.80x	0.89x
Revenue Growth	-	-	-	-	-	-	-	-	-100%

Frequently Asked Questions

Growth & Financials

Kezar Life Sciences, Inc. (KZR) saw revenue decline by 100.0% over the past year.

Kezar Life Sciences, Inc. (KZR) reported a net loss of $61.7M for fiscal year 2024.

Dividend & Returns

Kezar Life Sciences, Inc. (KZR) has a return on equity (ROE) of -55.0%. Negative ROE indicates the company is unprofitable.

Kezar Life Sciences, Inc. (KZR) had negative free cash flow of $56.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Kezar Life Sciences, Inc. (KZR) 10-Year Financial Performance & Capital Metrics

KZR • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0 -100.0%
EBITDA -$90M +18.8%
Net Income -$84M +17.8%
EPS (Diluted) -1.15 +17.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -55% -23.5%
ROIC -51.8% -30.7%
Debt/Equity 0.14 +37.1%
Interest Coverage -56.88 +20.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM35.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM-539.39%

ROCE

10Y Avg-41.96%

5Y Avg-39.5%

3Y Avg-43.04%

Latest-55.27%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	7M	0
Revenue Growth %	-	-	-	-	-	-	-	-	-1%
Cost of Goods Sold+	154K	175K	690K	1.3M	1.54M	1.51M	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-154K	-175K	-690K	-1.3M	-1.54M	-1.51M	0	7M	0
Gross Margin %	-	-	-	-	-	-	-	1%	-
Gross Profit Growth %	-	-0.14%	-2.94%	-0.89%	-0.19%	0.02%	1%	-	-1%
Operating Expenses+	8.99M	8.75M	24.73M	36.68M	41.46M	53.15M	71.16M	118.42M	90.61M
OpEx % of Revenue	-	-	-	-	-	-	-	16.92%	-
Selling, General & Admin	1.62M	2.28M	6.59M	8.68M	10.43M	15.72M	20.15M	26.54M	23.39M
SG&A % of Revenue	-	-	-	-	-	-	-	3.79%	-
Research & Development	7.37M	6.47M	18.14M	28M	31.04M	38.94M	51.01M	85.7M	65.74M
R&D % of Revenue	-	-	-	-	-	-	-	12.24%	-
Other Operating Expenses	0	0	0	0	0	-1.51M	0	6.19M	1.47M
Operating Income+	-8.99M	-8.75M	-24.73M	-37.98M	-43.01M	-54.66M	-71.16M	-111.42M	-90.61M
Operating Margin %	-	-	-	-	-	-	-	-15.92%	-
Operating Income Growth %	-	0.03%	-1.83%	-0.54%	-0.13%	-0.27%	-0.3%	-0.57%	0.19%
EBITDA+	-8.84M	-8.57M	-24.04M	-36.68M	-41.46M	-53.15M	-70.14M	-110.36M	-89.56M
EBITDA Margin %	-	-	-	-	-	-	-	-15.77%	-
EBITDA Growth %	-	0.03%	-1.8%	-0.53%	-0.13%	-0.28%	-0.32%	-0.57%	0.19%
D&A (Non-Cash Add-back)	154K	175K	690K	1.3M	1.54M	1.51M	1.02M	1.07M	1.04M
EBIT	-8.99M	-8.52M	-23.17M	-35.72M	-41.8M	-54.47M	-67.05M	-100.32M	-82.14M
Net Interest Income+	0	0	0	2.25M	1.21M	29K	2.92M	9.55M	6.87M
Interest Income	0	232K	1.56M	2.25M	1.21M	188K	4.11M	11.1M	8.46M
Interest Expense	0	0	0	0	0	159K	1.19M	1.55M	1.59M
Other Income/Expense	0	232K	1.56M	2.25M	1.21M	29K	2.92M	9.55M	6.87M
Pretax Income+	-8.99M	-8.52M	-23.17M	-35.72M	-41.8M	-54.63M	-68.24M	-101.87M	-83.74M
Pretax Margin %	-	-	-	-	-	-	-	-14.55%	-
Income Tax+	0	0	0	-635K	-58K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-8.99M	-8.52M	-23.17M	-35.09M	-41.74M	-54.63M	-68.24M	-101.87M	-83.74M
Net Margin %	-	-	-	-	-	-	-	-14.55%	-
Net Income Growth %	-	0.05%	-1.72%	-0.51%	-0.19%	-0.31%	-0.25%	-0.49%	0.18%
Net Income (Continuing)	-8.99M	-8.52M	-23.17M	-35.09M	-41.74M	-54.63M	-68.24M	-101.87M	-83.74M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.69	-0.65	-1.22	-1.65	-0.95	-1.04	-1.01	-1.40	-1.15
EPS Growth %	-	0.06%	-0.88%	-0.35%	0.42%	-0.09%	0.03%	-0.39%	0.18%
EPS (Basic)	-0.69	-0.65	-1.22	-1.65	-0.95	-1.04	-1.01	-1.40	-1.15
Diluted Shares Outstanding	13.02M	13.02M	19.02M	19.08M	44M	52.76M	67.37M	72.55M	72.9M
Basic Shares Outstanding	13.02M	13.02M	19.02M	19.08M	44M	52.76M	67.37M	72.55M	72.9M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.49M	52.33M	109.81M	81.13M	144.81M	211.65M	285.72M	206.95M	137.49M
Cash & Short-Term Investments	9.75M	51.03M	107.43M	78.21M	140.45M	208.35M	276.56M	201.37M	132.25M
Cash Only	9.75M	51.03M	24.18M	14.95M	21.23M	62.88M	40.46M	35.49M	41.75M
Short-Term Investments	0	0	83.25M	63.26M	119.22M	145.47M	236.1M	165.88M	90.5M
Accounts Receivable	0	0	0	642K	766K	0	0	2.29M	424K
Days Sales Outstanding	-	-	-	-	-	-	-	119.46	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	598K	508K	489K	406K	865K	729K	0	251K	351K
Total Non-Current Assets+	937K	1.9M	4.88M	8.38M	7.03M	6.28M	13.85M	14.29M	7.19M
Property, Plant & Equipment	862K	1.54M	4.59M	8.1M	6.75M	6M	13.17M	8.69M	4.78M
Fixed Asset Turnover	-	-	-	-	-	-	-	0.81x	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	13K	13K	0	0	0	0	0	0	0
Other Non-Current Assets	62K	343K	282K	282K	282K	282K	674K	5.59M	2.42M
Total Assets+	11.42M	54.22M	114.68M	89.51M	151.84M	217.93M	299.57M	221.24M	144.68M
Asset Turnover	-	-	-	-	-	-	-	0.03x	-
Asset Growth %	-	3.75%	1.12%	-0.22%	0.7%	0.44%	0.37%	-0.26%	-0.35%
Total Current Liabilities+	651K	1.48M	3.34M	6M	6.44M	8.21M	11M	17.74M	20.33M
Accounts Payable	466K	547K	193K	823K	2.36M	2.03M	2.48M	8.25M	3.65M
Days Payables Outstanding	1.1K	1.14K	102.09	230.9	557.43	490.21	-	-	-
Short-Term Debt	0	0	0	900K	1.04M	0	0	3.01M	5.22M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	51K	515K	2.41M	2.99M	1.69M	1.97M	2.69M	2.77M	5.22M
Current Ratio	16.11x	35.26x	32.91x	13.52x	22.48x	25.77x	25.98x	11.66x	6.76x
Quick Ratio	16.11x	35.26x	32.91x	13.52x	22.48x	25.77x	25.98x	11.66x	6.76x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	28.2M	78.42M	2.55M	5.46M	4.42M	12.85M	18.7M	15.92M	7.44M
Long-Term Debt	0	0	0	0	0	9.62M	9.83M	10.07M	5.11M
Capital Lease Obligations	0	0	0	5.46M	4.42M	3.22M	8.87M	5.85M	2.33M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	28.2M	78.42M	2.55M	0	0	0	0	0	0
Total Liabilities	28.85M	79.91M	5.88M	11.47M	10.86M	21.06M	29.7M	33.66M	27.77M
Total Debt+	0	0	0	6.36M	5.46M	14.04M	21.26M	18.93M	16.18M
Net Debt	-9.75M	-51.03M	-24.18M	-8.59M	-15.76M	-48.84M	-19.19M	-16.56M	-25.57M
Debt / Equity	-	-	-	0.08x	0.04x	0.07x	0.08x	0.10x	0.14x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-343.77x	-60.05x	-71.89x	-56.88x
Total Equity+	-17.43M	-25.69M	108.8M	78.05M	140.98M	196.88M	269.87M	187.57M	116.92M
Equity Growth %	-	-0.47%	5.24%	-0.28%	0.81%	0.4%	0.37%	-0.3%	-0.38%
Book Value per Share	-1.34	-1.97	5.72	4.09	3.20	3.73	4.01	2.59	1.60
Total Shareholders' Equity	-17.43M	-25.69M	108.8M	78.05M	140.98M	196.88M	269.87M	187.57M	116.92M
Common Stock	1K	1K	19K	19K	46K	56K	68K	73K	7K
Retained Earnings	-17.51M	-26.03M	-49.2M	-84.28M	-126.02M	-180.65M	-248.89M	-350.76M	-434.5M
Treasury Stock	-232K	-451K	0	0	0	0	0	0	0
Accumulated OCI	-150K	-111K	-203K	-196K	-137K	-291K	-923K	-130K	-162K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.76M	-8.11M	-20.79M	-29.88M	-36.95M	-42.44M	-58.85M	-81.64M	-74.21M
Operating CF Margin %	-	-	-	-	-	-	-	-11.66%	-
Operating CF Growth %	-	0.17%	-1.56%	-0.44%	-0.24%	-0.15%	-0.39%	-0.39%	0.09%
Net Income	-8.99M	-8.52M	-23.17M	-35.09M	-41.74M	-54.63M	-68.24M	-101.87M	-83.74M
Depreciation & Amortization	154K	175K	690K	1.3M	1.54M	1.51M	1.02M	1.07M	1.04M
Stock-Based Compensation	128K	203K	1.99M	4.01M	4.94M	7.6M	14.01M	18.14M	13.01M
Deferred Taxes	0	0	0	0	0	1.77M	0	0	0
Other Non-Cash Items	979K	472K	-370K	-979K	317K	91K	-1.18M	-3.68M	-3.23M
Working Capital Changes	-1.05M	30K	62K	881K	-2.01M	1.23M	-4.46M	4.71M	-1.3M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	-469K	81K	1.44M	2.21M	313K	1.22M	1.81M	6.35M	-3.15M
Cash from Investing+	-132K	-389K	-83.9M	20.42M	-56.5M	-28.44M	-91.39M	76.05M	80.43M
Capital Expenditures	-132K	-389K	-1.12M	-607K	-194K	-316K	-1.58M	-1.81M	-29K
CapEx % of Revenue	-	-	-	-	-	-	-	0.26%	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	10K	21.03K	-56.3K	-28.13K	-89.81K	5K	0
Cash from Financing+	36K	49.76M	77.91M	272K	99.64M	112.58M	127.86M	638K	103K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	36K	0	0	0	456K	2.08M	1.32M	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.89M	-8.5M	-21.91M	-30.48M	-37.14M	-42.75M	-60.42M	-83.45M	-74.24M
FCF Margin %	-	-	-	-	-	-	-	-11.92%	-
FCF Growth %	-	0.14%	-1.58%	-0.39%	-0.22%	-0.15%	-0.41%	-0.38%	0.11%
FCF per Share	-0.76	-0.65	-1.15	-1.60	-0.84	-0.81	-0.90	-1.15	-1.02
FCF Conversion (FCF/Net Income)	1.09x	0.95x	0.90x	0.85x	0.89x	0.78x	0.86x	0.80x	0.89x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-55.75%	-37.56%	-38.12%	-32.34%	-29.24%	-44.54%	-55%
Return on Invested Capital (ROIC)	-	-	-469.78%	-36.97%	-33.14%	-30%	-26.77%	-39.63%	-51.8%
Gross Margin	-	-	-	-	-	-	-	100%	-
Net Margin	-	-	-	-	-	-	-	-1455.29%	-
Debt / Equity	-	-	-	0.08x	0.04x	0.07x	0.08x	0.10x	0.14x
Interest Coverage	-	-	-	-	-	-343.77x	-60.05x	-71.89x	-56.88x
FCF Conversion	1.09x	0.95x	0.90x	0.85x	0.89x	0.78x	0.86x	0.80x	0.89x
Revenue Growth	-	-	-	-	-	-	-	-	-100%

Frequently Asked Questions

Growth & Financials

Kezar Life Sciences, Inc. (KZR) saw revenue decline by 100.0% over the past year.

Kezar Life Sciences, Inc. (KZR) reported a net loss of $61.7M for fiscal year 2024.

Dividend & Returns

Kezar Life Sciences, Inc. (KZR) has a return on equity (ROE) of -55.0%. Negative ROE indicates the company is unprofitable.

Kezar Life Sciences, Inc. (KZR) had negative free cash flow of $56.7M in fiscal year 2024, likely due to heavy capital investments.